Visudyne (verteporfin for injection) is a light-activated drug used in photodynamic therapy for the treatment of patients with redominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. Visudyne offers an anatomical treatment that occludes mature vessels that may be expressing less or no VEGF. It works to effect vaso-occlusion of the arteriolarized neovessels that may be the cause of persistent activity.*

*Persistent activity is defined herein as exudative manifestations that continue despite anti-VEGF treatments

Focus on Access

For Information on Reimbursement and Patient Assistance Services, call the FOCUS ON ACCESS Hotline, (866)-272-8838 (Monday-Friday, 9 AM to 5 PM EST).

Download the Focus on Access Enrollment Form 


Visudyne(verteporfin for injection) therapy is indicated for the treatment of patients with redominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.


  • Visudyne (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
  • Standard precautions should be taken during infusion of Visudyne to avoid extravasation, including but not limited to:
    • A free-flowing intravenous (IV) line should be established before starting Visudyne infusion and the line should be carefully monitored.
    • Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible, preferably the antecubital, be used for injection.
    • Small veins in the back of the hand should be avoided.
  • Extravasation of Visudyne, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site. If extravasation does occur, the infusion should be stopped immediately. The extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of local burn, which could be severe. Cold compresses should be applied to the injection site. Oral medication for pain relief may be administered.
  • Following injection with Visudyne, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
  • Patients who experience severe of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician.
  • The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including scotoma).

Click here for full Prescribing Information for Visudyne.

Preparation and Infusion Video : Understanding and Managing Persistent Activity in Wet AMD

Vitreoretinal surgical videos showing the management of retinal detachment, vitrectomy, macular holes, and more. Click below to watch the webinar on

Insight on persistent disease activity in wet AMD

Click below to view a video presentation, given by retina specialist Dr. Scott Cousins:

Visudyne (verteporfin for injection) : Additional information

Visudyne is a trademark of Novartis AG under license.

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25(2):111-118
2. Cousins et al, unpublished, presented at Royal Hawaiian Eye, 2014. 3. Slakter JS. What to do when anti-VEGF therapy “fails.” Retinal Physician website. Published June 2010. Accessed March 17, 2014.
4. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148(1):70-78.
5. Schmidt-Erfurth U, Kriechbaum K, Oldag A. Three-Dimensional Angiography of Classic and Occult Lesion Types in Choroidal Neovascularization. IOVS 2007;48(4):1751-1760.
6. Cousins SW. Controversies in Long-term AMD Management. Retinal Physician Website. Published January 2010. Accessed March 20, 2014.